The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis.

Mohammad Amin HabibiMohammad Sina MirjaniMuhammad Hussain AhmadvandPouria DelbariOmid Alasti

Published in: European journal of clinical pharmacology (2024)

Dabrafenib and trametinib demonstrate promising anti-tumor efficacy in gliomas, particularly low-grade tumors, achieving durable disease stabilization in many patients. However, toxicity significantly limited tolerability. Additional research should further examine efficacy and refine safe administration protocols across glioma subtypes.

Keyphrases

low grade
high grade
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
oxidative stress
open label
clinical trial
patient reported outcomes